http://doi.org/10.31288/oftalmolzh200962529

PREDICTABILITY OF RELAPSE OF THE LACRIMAL GLAND TUMOR OF EPITHELIAL GENESIS WITH THE AID OF ONCOMARKERS REA AND SA-19-9

Polyakova S. I.

Odessa, Ukraine

The estimation of the level SA-19-9 and REA in the peripheral blood of 33 patients with LGTEG was carried out, the middle age was (46.8 ± 16.6), 14 men and 19 women. Dynamics of the level SA-19-9 and REA in 3 and 6 months after treatment was followed up in 32 patients. The period of follow up of the patients was from 6 months to 8 years.

Relapses of LGTEG developed in 9 patients in 6 months — 5 years after the treatment, including patients with malignant (cancer in the pleomorphic adenoma, adenocarcinoma and adenocystic carcinoma) and benign (pleo-morphic adenoma, mixoma, onocytoma) LGTEG.

In developed relapse of the tumor there was established a reliable increase in the contents of oncomarker SA-19- 9in the blood serum before the treatment and its increase in the dynamics of follow-up (r = 0.0002).

The level of oncomarker REA in the blood serum of patients with LGTEG with developed relapse of the tumor before the treatment does not exceed standard but it also grows in the dynamics of follow-up (r = 0.006).

Increase in the level of oncomarkers REA and SA-19-9 in the blood serum of the patients with LGTEG in the dynamics of follow-up is expressed by the predominance of the positive test (+/+) in simultaneous estimation of both markers, and can be the prognostic index of the possible development of the tumor relapse suitable for monitoring of the treatment effectiveness.

The patients with values of REF and SA-19-9 higher than standard in the dynamics of follow-up can be considered as a risk group of possible tumor relapse and require a constant clinical follow-up.

 

References

1.Бровкина А. Ф. Болезни орбиты: Руководство для вра-чей / Алевтина Федоровна Бровкина. — 2-е изд. — М.: ООО «Медицинское информационное агентство», 2008. — 256 с.

2.Диагностическая иммуноцитология опухолей / Д. Ф. Глузман, Л. М. Скляренко, В. А. Надгорная, И. А. Крячок. — Киев: «Морион», 2003. — С. 6-15.

3.Иммуноцитохимическая диагностика злокачественных экссудатов / Д. Ф. Глузман, И. В. Абраменко, Л. М. Скляренко, Г. В. Писнячевская. — Киев: «Наукова думка», 1993. — С. 11-23.

4.Полякова С. И. Дифференциалъная диагностика и эффективностъ лечения новообразований слезной железы различного гистогенеза: автореф. дис. ... канд. мед. наук: спец. 14.00.08 «Глазные болезни». — Одесса, 1988. — 17 с.

5.Chuo Ni. Lacrimal gland tumours: A clinico-pathological analysis of 160 cases // Chuo Ni, Shu Chu Cheg, Druja T., Tao Yu Cheng // Ophthalm. Clin. — 1982. — Vol. 22, № 1. — P. 99-120.

Crossref   PubMed

6.De Lellis Eds R. A. Advances in immunohistochemistry / Eds. R. A. De Lellis. — New York: Raven press, 1988. —496 p.

7.Esmaeli B. Surgical management of locally advanced adenoid cystic carcinoma of the lacrimal gland / B. Esmaeli, D. Golib, M. Kies, F. Demonte // Ophthalm. Plast. Reconstr. Surg. — 2006. — Vol. 22, № 5. — P. 366-370.

Crossref    PubMed

8.Hartwick R. W. In situ adenocarcinoma ex pleopmor-phic adenoma of the lacrimal gland / R. W. Hartwich, P. a. Shaw, J. R. Srigley, J. J. Hurwitz // Canad. J. Ophthalmol. — 1990. — Vol. 25, № 4. — P. 213-217.

9.Kupchik Eds H. Z. Cancer diagnosis in vitro using mono-clonal antibodies / Eds. H. Z. Kupchik. — London: Marcel Dekker, 1988. — 322 p.

10.Rose Geoffrey E. Pleomorphic adenoma of the lacrimal gland / Geoffrey E. Rose, John E. Wright // Brit. J. Ophthalmol. — 1992. — Vol. 76, № 7. — P. 398-401.

Crossref    PubMed 

11.Rosenbaum P. Acinic Cell Carcinoma of the Lacrimal Glands / P. Rosenbaum, P. Mahadevia, L. Goodman // Arch. Ophthal. — 1995. — Vol. 113, № 6. — P. 781785.

Crossref    PubMed